CH637369A5 - Zinc salt of N-acetyl-6-aminocaproic acid, and a process for its preparation - Google Patents
Zinc salt of N-acetyl-6-aminocaproic acid, and a process for its preparation Download PDFInfo
- Publication number
- CH637369A5 CH637369A5 CH85579A CH85579A CH637369A5 CH 637369 A5 CH637369 A5 CH 637369A5 CH 85579 A CH85579 A CH 85579A CH 85579 A CH85579 A CH 85579A CH 637369 A5 CH637369 A5 CH 637369A5
- Authority
- CH
- Switzerland
- Prior art keywords
- zinc
- acetyl
- zinc salt
- aminocaproic acid
- preparation
- Prior art date
Links
- WDSCBUNMANHPFH-UHFFFAOYSA-N acexamic acid Chemical compound CC(=O)NCCCCCC(O)=O WDSCBUNMANHPFH-UHFFFAOYSA-N 0.000 title claims description 25
- 238000000034 method Methods 0.000 title claims description 13
- 150000003751 zinc Chemical class 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000002798 polar solvent Substances 0.000 claims description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 3
- 229960001763 zinc sulfate Drugs 0.000 claims description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 3
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 claims 1
- 239000011877 solvent mixture Substances 0.000 claims 1
- 229910000010 zinc carbonate Inorganic materials 0.000 claims 1
- 235000004416 zinc carbonate Nutrition 0.000 claims 1
- 239000011667 zinc carbonate Substances 0.000 claims 1
- 229960004582 acexamic acid Drugs 0.000 description 19
- 230000000694 effects Effects 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000011701 zinc Substances 0.000 description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 230000000767 anti-ulcer Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 229960002684 aminocaproic acid Drugs 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229960002895 phenylbutazone Drugs 0.000 description 2
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000010470 Ageusia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- ZPACYDRSPFRDHO-ROBAGEODSA-N Gefarnate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C ZPACYDRSPFRDHO-ROBAGEODSA-N 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 206010020989 Hypogeusia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 206010000596 acrodermatitis enteropathica Diseases 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000011361 granulated particle Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 235000019570 hypogeusia Nutrition 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- MOYZEMOPQDTDHA-YQYZCKNZSA-N norhyoscine Chemical compound C1([C@H](C(=O)OC2C[C@@H]3N[C@@H]([C@H]4O[C@H]43)C2)CO)=CC=CC=C1 MOYZEMOPQDTDHA-YQYZCKNZSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- UOURRHZRLGCVDA-UHFFFAOYSA-D pentazinc;dicarbonate;hexahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Zn+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2].[O-]C([O-])=O.[O-]C([O-])=O UOURRHZRLGCVDA-UHFFFAOYSA-D 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- -1 pomades Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229960001365 sodium acexamate Drugs 0.000 description 1
- UIEHVVUIWRNUKL-UHFFFAOYSA-M sodium;6-acetamidohexanoate Chemical compound [Na+].CC(=O)NCCCCCC([O-])=O UIEHVVUIWRNUKL-UHFFFAOYSA-M 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
- C07D223/10—Oxygen atoms attached in position 2
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES466455A ES466455A1 (es) | 1978-01-30 | 1978-01-30 | Procedimiento para la preparacion de un nuevo derivado de 6-caprolactama. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH637369A5 true CH637369A5 (en) | 1983-07-29 |
Family
ID=8475373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH85579A CH637369A5 (en) | 1978-01-30 | 1979-01-29 | Zinc salt of N-acetyl-6-aminocaproic acid, and a process for its preparation |
Country Status (6)
| Country | Link |
|---|---|
| BE (1) | BE873688A (enrdf_load_stackoverflow) |
| CH (1) | CH637369A5 (enrdf_load_stackoverflow) |
| DE (1) | DE2901914C2 (enrdf_load_stackoverflow) |
| ES (1) | ES466455A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2415625A1 (enrdf_load_stackoverflow) |
| IT (1) | IT1119259B (enrdf_load_stackoverflow) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2009266A6 (es) * | 1988-04-27 | 1989-09-16 | Vinas Lab | Procedimiento para la preparacion de un derivado del acido n-acetil-6-aminohexanoico. |
| ES2010057A6 (es) * | 1988-12-26 | 1989-10-16 | Vinas Lab | Procedimiento para la preparacion de un derivado del acido acexamico. |
| FR2773486B1 (fr) * | 1998-01-13 | 2001-04-06 | Oreal | Composition de soin des levres contenant de l'acide acexamique, ses utilisations |
| CN103709060A (zh) * | 2013-10-16 | 2014-04-09 | 南阳利欣药业有限公司 | 一种制备醋氨己酸锌的方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2332M (enrdf_load_stackoverflow) * | 1963-01-08 | 1964-03-13 | Rowa Ltd | |
| FR2062873B1 (enrdf_load_stackoverflow) * | 1969-09-25 | 1973-07-13 | Choay Sa |
-
1978
- 1978-01-30 ES ES466455A patent/ES466455A1/es not_active Expired
-
1979
- 1979-01-18 DE DE2901914A patent/DE2901914C2/de not_active Expired
- 1979-01-18 FR FR7901856A patent/FR2415625A1/fr active Granted
- 1979-01-24 BE BE193064A patent/BE873688A/xx not_active IP Right Cessation
- 1979-01-29 IT IT67187/79A patent/IT1119259B/it active
- 1979-01-29 CH CH85579A patent/CH637369A5/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IT7967187A0 (it) | 1979-01-29 |
| DE2901914C2 (de) | 1982-12-09 |
| ES466455A1 (es) | 1978-10-16 |
| BE873688A (fr) | 1979-05-16 |
| IT1119259B (it) | 1986-03-10 |
| DE2901914A1 (de) | 1979-08-02 |
| FR2415625A1 (fr) | 1979-08-24 |
| FR2415625B1 (enrdf_load_stackoverflow) | 1983-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3152175C2 (enrdf_load_stackoverflow) | ||
| DE2549783C3 (de) | Triglyceride mit entzündungshemmender Wirkung | |
| DE2756216A1 (de) | Phenylalkylhydroxamsaeuren, ihre herstellung und verwendung in arzneimitteln | |
| DE2913211A1 (de) | 2-(2-thenoylthio)propionylglycin, verfahren zu seiner herstellung und es enthaltende pharmazeutische mittel | |
| DE2634903C2 (de) | Tetrahydrothieno-[3,2-c]-pyridin-Derivate und sie enthaltende Arzneimittel | |
| CH637369A5 (en) | Zinc salt of N-acetyl-6-aminocaproic acid, and a process for its preparation | |
| DE2128607A1 (de) | Neue Morphinanderivate | |
| DE2434929C2 (de) | p-Acetylaminophenolester von Phenylsalicylsäuren, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE2828933C3 (enrdf_load_stackoverflow) | ||
| DE2239768A1 (de) | Neue heparinester mit verlaengerter wirkung | |
| DE3337925C2 (de) | N-(6-Aminopurinyl)-4-hydroxy-2-methyl-2H-1,2-benzothiazin-3-carboxamid-1,1-dioxid, Verfahren zu dessen Herstellung und seine Verwendung | |
| DE2144568A1 (de) | Neue Derivate der Phenyl-5-pyrazolcarbonsäuren-3, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| LU87406A1 (de) | Tromethamin-salz von 1-methyl-beta-oxo-alpha-(phenylcarbamoyl)-2-pyrrolproprionitril | |
| DE2123380C3 (de) | p-Aminophenol-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende therapeutische Mittel | |
| DE1493618A1 (de) | Cumarinderivate und ein Verfahren zu ihrer Herstellung | |
| DE2535799C3 (de) | N'- [1 -(p-Chlorbenzoyl)-5-methoxy-2-methyl-3indolyl-acetoxy- alkyl] -N-(N-benzoyl- N'JS'-di-npropyl-DL-isoglutaminyloxy- alkyD-piperazine und diese enthaltene Entzündungen und Gelenksaffektionen hemmende Präparate | |
| DE69012213T2 (de) | Phenylessigsäurederivat. | |
| DE2839311C2 (de) | Pharmazeutisches Präparat gegen Geschwüre | |
| DE2827932A1 (de) | Biphenylsulfonyliminoverbindungen | |
| DE2442303A1 (de) | Salze von dl- oder l-tryptophanderivaten, verfahren zu ihrer herstellung und diese enthaltende mittel | |
| DE2338350A1 (de) | Beta-(3,4-dialkanoyloxyphenyl)-lalanin-ester | |
| DE69505530T2 (de) | Guanylsäure derivate und ihre verwendung als arzneimittel | |
| DE1593317C3 (de) | Verfahren zur Herstellung eines Wismut-Aluminium-Doppelpektates | |
| DE2316914C3 (de) | 4-(p-Chlorphenoxyacetylamino) benzoesäurediäthylamino-äthylester-pchlorphenoxyisobutyrat Verfahren zu seiner Herstellung und diese Verbindung enthaltende Arzneimittel | |
| DE1543150C (de) | Tetracyclin-guajakol-4-su\fonat und Verfahren zu dessen Herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |